Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axon Enterprise, Inc. filings document operating results and corporate actions for a public safety technology company with Software & Services and Connected Devices activities. Form 8-K reports include shareholder letters on financial results and outlooks, product demand across TASER devices, Axon Body cameras, Axon Evidence, AI products, counter-drone offerings and real-time operations, as well as material-event disclosures tied to capital structure.
Proxy materials cover board composition, shareholder meeting matters, executive compensation and equity awards. Other 8-K and 8-K/A filings record director election updates and the redemption and settlement of 0.50% convertible senior notes due 2027, including the disclosure that no convertible notes remained outstanding after the redemptions and conversions.
Joshua Isner, President of Axon Enterprise, Inc. (AXON), reported multiple dispositions of common stock in a Form 4. On 08/13/2025 he had 11,937 shares withheld to satisfy tax liabilities from vested restricted stock units. On 08/15/2025 he sold a series of 13 tranches totaling 15,919 shares under a Rule 10b5-1 trading plan adopted on 08/21/2024; the reported weighted average prices for those trades ranged from $739.0411 to $751.35 with detailed price ranges disclosed for each tranche. Following these transactions the filing reports 238,379 shares beneficially owned. The Form 4 is signed by attorney-in-fact Isaiah Fields on 08/15/2025.
Insider purchase reported: Axon Enterprise director Hadi Partovi acquired 1,358 shares of Axon common stock on 08/13/2025 at a weighted average price of $739.9998 per share. After the purchase, Partovi beneficially owns 237,938 shares. The filing notes the trade was executed in multiple trades with prices ranging from $739.81 to $740.00 and that the reported price reflects a weighted average. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact.
Axon Enterprise, Inc. filed a Form 144 notifying of a proposed sale of 15,919 shares of common stock through Merrill Lynch on 08/15/2025 on Nasdaq with an aggregate market value of $11,879,088.00. The shares were acquired as an equity award from the issuer on 08/13/2025 and payment is indicated as cash. The filer also reported four prior sales during the past three months totaling 15,810 shares on 05/21/2025, 06/17/2025, 08/07/2025 and 08/12/2025 with combined gross proceeds of $12,110,841.00. The filing includes the required attestation that the seller is not aware of undisclosed material adverse information.
Axon Enterprise, Inc. filed a Form 13F reporting institutional holdings value of $144,000,000 across 1 reported position. The report is signed by Isaiah Fields, Chief Legal Officer, and dated 08-14-2025.
Patrick W. Smith, Axon CEO and director, reported multiple open-market sales of common stock executed pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The Form 4 lists 16 separate sales on 08/11/2025 totaling 10,000 shares executed in multiple trades with reported weighted-average prices by tranche. Reported per-share execution ranges span approximately $821.50 to $839.11. After the reported transactions the filing shows the reporting person beneficially owned 3,053,982 shares of Axon.
The filing discloses the trades were made under a written 10b5-1 plan and provides weighted-average sale prices for each block; the submission is a routine insider disclosure of securities dispositions and the specific trade execution details are available upon request to the SEC staff, issuer or security holders per the filer’s statement.
Joshua Isner, an officer (President) of Axon Enterprise, reported multiple sales of the company’s common stock executed on 08/07/2025. The Form 4 lists five sale tranches that together total 2,500 shares sold, with reported weighted-average sale prices of $867.4875, $868.50, $869.7092, $871.2756 and $872.1513, and disclosed execution price ranges approximately $867.15 to $872.34.
After these transactions the reporting person is shown as directly owning 266,235 shares. No derivative securities were reported and the filer offers to provide full trade-level details to the SEC or security holders upon request.
Caitlin E. Kalinowski, identified as a director of Axon Enterprise (AXON), reported two separate sales of common stock on 08/07/2025 totaling 580 shares.
The filing shows a sale of 476 shares at a weighted-average price of $870.7414 and a sale of 104 shares at a weighted-average price of $872.0066. The two report lines list beneficial ownership amounts of 4,799 and 4,695 shares following the respective transactions. The Form 4 was executed through an attorney-in-fact and discloses the transaction details and weighted-average prices without additional commentary.
In this Form 144 notice for Axon Enterprise, Inc., the filer reports an intended sale of 10,000 shares of common stock through UBS Financial Services on Nasdaq with an aggregate market value of $8,428,900 and an approximate sale date of 08/11/2025. The shares were acquired on 11/15/2021 via an option exercise and paid in cash. The filing lists 78,504,440 shares outstanding, so the proposed sale represents about 0.0127% of outstanding shares.
The form shows no securities sold by the filer in the past three months and includes the standard Rule 144 representation that the filer does not possess undisclosed material adverse information. A broker is named and the transaction mechanics (option exercise, cash payment) are disclosed.